Diagnostic value of transvaginal ultrasound combined with serum CA125 and HE4 in differentiating benign and malignant ovarian tumors

Background: This study aimed to evaluate the diagnostic value of transvaginal ultrasound combined with the serum carbohydrate antigen125 (CA125) and Human Epididymis Protein 4 (HE4) in distinguishing benign from malignant ovarian tumors. Methods: The data of 140 patients with ovarian tumors were retrospectively analyzed. According to the histopathological diagnosis divided into benign group (109 cases) and malignant group (31 cases). Clinical data, serum biomarkers and transvaginal ultrasound were collected. Multivariate logistic regression and receiver operating characteristic (ROC) curve were used to analyze the diagnostic value of each parameter. Results: No significant differences in body mass index (BMI) or history of abortion between the two groups (p > 0.05). The proportion of postmenopausal patients was significantly higher in malignant group than benign group (p < 0.05). The pulsatility index (PI) and systolic-to-diastolic ratio (S/D) were significantly lower in the benign group than malignant group (p < 0.05), the resistance index (RI) was lower in the benign group but did not reach statistical significance (p > 0.05). Serum CA125 and HE4 levels were significantly higher in the malignant group than benign group (p < 0.05). Multivariate logistic regression analysis showed that RI, PI, S/D, CA125 and HE4 were independent influencing factors for benign and malignant diagnosis of ovarian tumors (p < 0.05). ROC showed that RI, PI, S/D, CA125 and HE4 had diagnostic value, and the area under the curve (AUC) was 0.588, 0.643, 0.698, 0.735 and 0.711, respectively. The diagnostic accuracy of the above combination was the highest, with an AUC of 0.856. Conclusions: The diagnosis of benign and malignant ovarian tumors by transvaginal ultrasound is limited, and the detection of serum markers is not high. Transvaginal ultrasound combined with CA125 and HE4 can significantly improve the accuracy of diagnosis, and has high clinical application value.

Transvaginal ultrasound; Ovarian tumor; Serum biomarkers

[1] Castillo Simón AG, Martínez Ramos CV, Rodríguez Morales VV, Núñez Arana B, Dominguez Prado I, Muñoz Iglesias JL. Follicular thyroid carcinoma arising in a struma ovarii and femoral metastasis. Revista Española de Medicina Nuclear e Imagen Molecular. 2022; 41: 325–326.

[2] Cheng CC, Ting A, Chang, Yang WP. First case report of papillary thyroid carcinoma arising within a functional teratoma in Graves’ disease patient. Gynecological Endocrinology. 2021; 37: 955–958.

[3] Donato S, Simões H, Leite V. Malignant struma ovarii with concurrent thyroid cancer: outcomes during and after pregnancy. European Thyroid Journal. 2021; 10: 523–527.

[4] Leite C, Rodrigues P, Oliveira SL, Martins NN, Martins FN. Struma ovarii in bilateral ovarian teratoma-case report and literature review. Journal of Surgical Case Reports. 2021; 2021: rjab028.

[5] Leuștean L, Ungureanu MC, Preda C, Bilha SC, Obrocea F, Dănilă R, et al. Management of malignant struma ovarii: is aggressive therapy justified? Case report and literature review. Thyroid Research. 2022; 15: 14.

[6] Prentice J, Panter K, Attygalle A, Ind T, Prentice M. Pure T3 thyrotoxicosis from a Struma Ovarii characterised by a paradoxical rise in thyroxine on treatment. Endocrinology, Diabetes & Metabolism Case Reports. 2020; 2020: 19-0097.

[7] Rahma A, Mardiyana L, Fauziah D. Malignant struma ovarii: case report of an unusual ovarian tumor with CT imaging. Radiology Case Reports. 2022; 17: 1705–1708.

[8] Tamura N, Murakami K, Ozaki R, Takeuchi S, Ochiai A, Kawasaki Y, et al. Current state of management of struma ovarii and preoperative imaging features: a retrospective case series study of 18 patients at a single institution. Journal of Obstetrics and Gynaecology Research. 2023; 49: 1007–1011.

[9] Terzic M, Aimagambetova G, Norton M, Della Corte L, Marín-Buck A, Lisón JF, et al. Scoring systems for the evaluation of adnexal masses nature: current knowledge and clinical applications. Journal of Obstetrics and Gynaecology Research. 2021; 41: 340–347.

[10] Ye AQ, Reyes MF, Lester F, Ye J, Umetsu S, Poder L, et al. Boba sign with a twist—a variant presentation of a mature cystic teratoma complicated by torsion and rupture. Clinical Imaging. 2022; 83: 28–32.

[11] Abera SA, Molla DK, Abera KA, Adisu GD, Worku MA, Molla YD. Struma ovarii with papillary thyroid carcinoma and metastasis to the appendix: a case report and literature review. International Medical Case Reports Journal. 2023; 16: 571–578.

[12] Dumachița-Șargu G, Socolov R, Balan TA, Gafițanu D, Akad M, Balan RA. Struma ovarii during pregnancy. Diagnostics. 2024; 14: 1172.

[13] Iavarone I, Padovano M, Pasanisi F, Della Corte L, La Mantia E, Ronsini C. Meigs syndrome and elevated CA-125: case report and literature review of an unusual presentation mimicking ovarian cancer. Medicina. 2023; 59: 1684.

[14] Li S, Hong R, Yang J. Malignant struma ovarii with synchronous primary papillary thyroid cancer in the neck: a case report and literature review. Oncology Letters. 2024; 27: 174.

[15] Obeidat RA, Alshwayyat S, Alshwayyat TA, Rjoop A, Sharqiah QM. Presentation and treatment of two cases of malignant struma ovarii. BMC Womens Health. 2024; 24: 158.

[16] Qin H, Chen D, Jin S, Liu J, Gao B, Wang Y. Teratoma combined with struma ovarii and sarcomatoid carcinoma: a case report and review of the literature. BMC Womens Health. 2024; 24: 517.

[17] Stefanopol IA, Petecariu A, Baroiu L, Neagu AI, Bogdan-Goroftei RE, Nechifor A, et al. Giant benign struma ovarii with high-grade fever, elevated CA 125, and hormonal function in an adolescent patient. Children. 2023; 10: 856.